quantisnow
FeedTopReportsPricing
⌘K
Live feed
13:00:00·66d
PRRelease
Fate Therapeutics Inc. logo
Century Therapeutics Inc. logo

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

FATE· Fate Therapeutics Inc.IPSC· Century Therapeutics Inc.
Health Care
Original source

Companies

  • FATE
    Fate Therapeutics Inc.
    Health Care
  • IPSC
    Century Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Feb 25IPSCUpdateTD Cowen-
  • Oct 31FATEUpdateH.C. Wainwright$5.00
  • Oct 27FATEUpdateWedbush$7.00
  • Nov 18FATEUpdateBofA Securities-
  • Aug 8IPSCUpdateRodman & Renshaw$6.00
  • Jun 17FATEUpdatePiper Sandler$6.00

Related

  • INSIDER3h
    Amendment: SEC Form 4 filed by Director Redmile Group, Llc
  • INSIDER1d
    SEC Form 4 filed by Redmile Group, Llc
  • SEC1d
    Amendment: SEC Form SCHEDULE 13D/A filed by Fate Therapeutics Inc.
  • SEC7d
    SEC Form PRE 14A filed by Century Therapeutics Inc.
  • PR7d
    Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting
  • INSIDER13d
    SEC Form 4 filed by Murphy Martin Patrick
  • INSIDER13d
    SEC Form 3 filed by new insider Murphy Martin Patrick
  • PR14d
    Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022